Benzothiophene containing Rho kinase inhibitors: Efficacy in an animal model of glaucoma

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 11, 2010, Pages 3361-3366

  Davis, Robert L ^a   Kahraman, Mehmet ^a,c   Prins, Thomas J ^a   Beaver, Yan ^a   Cook, Travis G ^a   Cramp, Jessica ^a   Cayanan, Charmagne S ^a   Gardiner, Elisabeth M M ^a   McLaughlin, Marsha A ^b   Clark, Abbot F ^b   Hellberg, Mark R ^b   Shiau, Andrew K ^a   Noble, Stewart A ^a   Borchardt, Allen J ^a  

^a Kalypsys Inc   (United States)

^b ALCON RESEARCH LTD   (United States)

^c Aragon Pharmaceuticals   (United States)

Author keywords

Adhesion; ATP competitive; Benzothiophene; Glaucoma; Impedance; Inhibitor; Kinase; Rho; ROCK

Indexed keywords

BENZOTHIOPHENE DERIVATIVE; RHO KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG EFFICACY; DRUG SCREENING; ENZYME ACTIVITY; GLAUCOMA; HIGH THROUGHPUT SCREENING; IMPEDANCE; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MONKEY; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; DISEASE MODELS, ANIMAL; GLAUCOMA; HAPLORHINI; HELA CELLS; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; THIOPHENES;

ANIMALIA;

EID: 77953292839     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.04.020     Document Type: Article

References (60)

1. Wettschureck N., and Offermanns S. J. Mol. Med. 80 (2002) 629
2. Bishop A.L., and Hall A. Biochem. J. 348 (2000) 241
3. Riento K., and Ridley A.J. Nat. Rev. Mol. Cell. Biol. 4 (2003) 446
4. Chang J., Xie M., Shah V.R., Schneider M.D., Entman M.L., Wei L., and Schwartz R.J. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 14495
5. Del Re D.P., Miyamoto S., and Brown J.H. J. Biol. Chem. 282 (2007) 8069
6. Haydont V., Bourgier C., and Vozenin-Brotons M.C. Br. J. Radiol. 80 (2007) S32
7. Moriyama T., and Nagatoya K. Drug News Perspect. 17 (2004) 29
8. Murata T., Arii S., Nakamura T., Mori A., Kaido T., Furuyama H., Furumoto K., Nakao T., Isobe N., and Imamura M. J. Hepatol. 35 (2001) 474
9. Amano M., Ito M., Kimura K., Fukata Y., Chihara K., Nakano T., Matsuura Y., and Kaibuchi K. J. Biol. Chem. 271 (1996) 20246
10. Fukata Y., Amano M., and Kaibuchi K. Trends Pharmacol. Sci. 22 (2001) 32
11. Ishizaki T., Naito M., Fujisawa K., Maekawa M., Watanabe N., Saito Y., and Narumiya S. FEBS Lett. 404 (1997) 118
12. Lohn, M.; Plettenburg, O.; Ivashchenko, Y.; Kannt, A.; Hofmeister, A.; Kadereit, D.; Schaefer, M.; Linz, W.; Kohlmann, M.; Herbert, J. M.; Janiak, P.; O'Connor, S. E.; Ruetten, H. Hypertension 2009.
13. Schirok H., Kast R., Figueroa-Perez S., Bennabi S., Gnoth M.J., Feurer A., Heckroth H., Thutewohl M., Paulsen H., Knorr A., Hutter J., Lobell M., Munter K., Geiss V., Ehmke H., Lang D., Radtke M., Mittendorf J., and Stasch J.P. ChemMedChem 3 (2008) 1893
14. Sehon C.A., Wang G.Z., Viet A.Q., Goodman K.B., Dowdell S.E., Elkins P.A., Semus S.F., Evans C., Jolivette L.J., Kirkpatrick R.B., Dul E., Khandekar S.S., Yi T., Wright L.L., Smith G.K., Behm D.J., Bentley R., Doe C.P., Hu E., and Lee D. J. Med. Chem. 51 (2008) 6631
15. Tanihara H., Inatani M., Honjo M., Tokushige H., Azuma J., and Araie M. Arch. Ophthalmol. 126 (2008) 309
16. Tawara S., and Shimokawa H. Yakugaku Zasshi 127 (2007) 501
17. Tokushige H., Inatani M., Nemoto S., Sakaki H., Katayama K., Uehata M., and Tanihara H. Invest. Ophthalmol. Vis. Sci. 48 (2007) 3216
18. Koga T., Awai M., Tsutsui J., Yue B.Y., and Tanihara H. Exp. Eye Res. 82 (2006) 362
19. Sessions E.H., Yin Y., Bannister T.D., Weiser A., Griffin E., Pocas J., Cameron M.D., Ruiz C., Lin L., Schurer S.C., Schroter T., LoGrasso P., and Feng Y. Bioorg. Med. Chem. Lett. 18 (2008) 6390
20. Dergham P., Ellezam B., Essagian C., Avedissian H., Lubell W.D., and McKerracher L. J. Neurosci. 22 (2002) 6570
21. Fournier A.E., Takizawa B.T., and Strittmatter S.M. J. Neurosci. 23 (2003) 1416
22. Kubo T., Hata K., Yamaguchi A., and Yamashita T. Curr. Pharm. Des. 13 (2007) 2493
23. Nagaoka T., Morio Y., Casanova N., Bauer N., Gebb S., McMurtry I., and Oka M. Am. J. Physiol. Lung Cell. Mol. Physiol. 287 (2004) L665
24. Oka M., Fagan K.A., Jones P.L., and McMurtry I.F. Br. J. Pharmacol. 155 (2008) 444
25. Shimokawa H., and Rashid M. Trends Pharmacol. Sci. 28 (2007) 296
26. Nakajima E., Nakajima T., Minagawa Y., Shearer T.R., and Azuma M. J. Pharm. Sci. 94 (2005) 701
27. Rao P.V., Deng P., Maddala R., Epstein D.L., Li C.Y., and Shimokawa H. Mol. Vis. 11 (2005) 288
28. Rao P.V., Deng P.F., Kumar J., and Epstein D.L. Invest. Ophthalmol. Vis. Sci. 42 (2001) 1029
29. 50 values, consistent with an ATP-competitive mechanism of action.
30. All synthesized compounds displayed spectral data (MS, NMR) consistent with their assigned structures. Compounds were tested as racemic mixtures when present as such. Synthetic methods can be found in Kahraman, M. et al., U.S. patent application 20080021026.
31. 50 but less than 100% efficacy. In separate experiments, reference compounds dissolved in water at 100 mM allowed us to test concentrations up to 100 μM and confirm 100% efficacy compared to the most potent control, Y-39983. We tested reversibility by aspirating compound-containing media and replacing with compound-free media after multiple washes. Reversibility was tested up to 24 h after compound addition, and was complete about 3 h after media replacement. In parallel 24 h cytotoxicity assays, there was no significant effect of compounds up to at least 30 μM.
32. Yoneda A., Multhaupt H.A., and Couchman J.R. J. Cell. Biol. 170 (2005) 443
33. Yarrow J.C., Totsukawa G., Charras G.T., and Mitchison T.J. Chem. Biol. 12 (2005) 385
34. Jaeger M.M., Dodane V., and Kachar B. J. Membr. Biol. 139 (1994) 41
35. Tang A.S., Chikhale P.J., Shah P.K., and Borchardt R.T. Pharm. Res. 10 (1993) 1620
36. Sinnett-Smith J., Lunn J.A., Leopoldt D., and Rozengurt E. Exp. Cell. Res. 266 (2001) 292
37. Atienza J.M., Yu N., Kirstein S.L., Xi B., Wang X., Xu X., and Abassi Y.A. Assay Drug Dev. Technol. 4 (2006) 597
38. Xi B., Yu N., Wang X., Xu X., and Abassi Y.A. Biotechnol. J. 3 (2008) 484
39. Pang I.H., Shade D.L., Clark A.F., Steely H.T., and DeSantis L. Curr. Eye Res. 13 (1994) 51
40. Sasaki Y., Suzuki M., and Hidaka H. Pharmacol. Ther. 93 (2002) 225
41. Chihara K., Amano M., Nakamura N., Yano T., Shibata M., Tokui T., Ichikawa H., Ikebe R., Ikebe M., and Kaibuchi K. J. Biol. Chem. 272 (1997) 25121
42. 2 Alexa-488 secondary antibody (Invitrogen) under conventional conditions. Images were acquired on a Zeiss Axiovert 200 M equipped with a Hamamatsu ORCA ER cooled CCD camera and OpenLab software (Improvision). Images were imported into Adobe Photoshop (v.10) for labeling and minor alterations in brightness only.
43. 50 of 0.36 ± 0.08 μM against ROCK. The other compounds had dramatically different effects quantitatively, qualitatively, or both. For example, imatinib caused a rapid, small magnitude increase in impedance, followed by a slow decrease to baseline over 3 h. Other compounds with different effects than ROCK inhibitors included 6-anilinoquinoline-5,8-quinone (guanylate cyclase inhibitor), 2′,5′-dideoxyadenosine (adenylate cyclase inhibitor), and nocodazole (microtubule polymerization inhibitor, tested at 2 μM). Treatment with blebbistatin (myosin II inhibitor, 10 or 1 μM) showed a dose-dependent effect similar to ROCK inhibitors, but with one-third the magnitude, while taxol (microtubule stabilizer, 0.1 or 0.01 μM) showed a similar low magnitude, non dose-dependent effect. Only cytochalasin D (actin polymerization inhibitor) or an RGD containing peptide with sequence GRGDTP (integrin inhibitor; a control peptide with sequence GRADSP was inactive) showed dose dependent effects at 10 and 1 μM strikingly similar to that of ROCK inhibitors. The effects of the last four, and especially the last two, compounds are consistent with their targets and expected effects on cell adhesion. Sorafenib, PD-184352, gefitinib, imatinib, and VX-745 were synthesized by Kalypsys; all other compounds in impedance validation experiments were purchased from commercial vendors.
44. Schroter T., Griffin E., Weiser A., Feng Y., and LoGrasso P. Biochem. Biophys. Res. Commun. 374 (2008) 356
45. Li W., Nelson D.P., Jensen M.S., Hoerrner R.S., Cai D., Larsen R.D., and Reider P.J. J. Org. Chem. 67 (2002) 5394
46. Jacobs M., Hayakawa K., Swenson L., Bellon S., Fleming M., Taslimi P., and Doran J. J. Biol. Chem. 281 (2006) 260
47. Yamaguchi H., Miwa Y., Kasa M., Kitano K., Amano M., Kaibuchi K., and Hakoshima T. J. Biochem. 140 (2006) 305
48. Schenone P., Sansebastiano L., and Mosti L. J. Heterocycl. Chem. 27 (1990) 295
49. Knochel P., and Singer R.D. Chem. Rev. 93 (1993) 2117
50. Marion N., Ecarnot E.C., Navarro O., Amoroso D., Bell A., and Nolan S.P. J. Org. Chem. 71 (2006) 3816
51. Prepared as described in Scheme 1; des-chloro 4 was used as an intermediate.
52. 3 in DCM.
53. 2, 3 h, 20%.
54. 2O), THF/MeOH (1:1), rt, 43%.
55. Compound 25 was tested at 10 μM for inhibition in functional assays of the following kinases (Invitrogen,% inhibition in parentheses if ≥50%): ALK4, AMPK, Aurora B (82), B-Raf, CaMK2α, CaMK4, CDK2/cyclinA, CDK5/p35, CK1α1, CK1ε1, CK2α1, DAPK3, EGFR, EphB4, Erk1, FGFR1, GSK3β, INSR, Jak2, Jnk1, Lck, Mek1, MKK6, MLK1, MAPKAPK2, MSK1 (94), p38α, p70S6K (55), Pak6, PDGFRα, PKA (67), PKCα, PKCε, PKN1 (53), RSK1, SGK1 (61), Src, TrkA, ZAP70.
56. Solubility was assessed by conventional kinetic assays, measuring absorbance after precipitate filtration from compounds initially in 100% DMSO, with calculation from known standards.
57. Chen T.M., Shen H., and Zhu C. Comb. Chem. High Throughput Screen. 5 (2002) 575
58. 3 in DCM.
59. Grass G.M., and Robinson J.R. J. Pharm. Sci. 77 (1988) 3
60. May J.A., McLaughlin M.A., Sharif N.A., Hellberg M.R., and Dean T.R. J. Pharmacol. Exp. Ther. 306 (2003) 301